SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology reported Q4 and full-year 2025 financial results,…

Kura Oncology, Inc. · PRESS-RELEASE filed Mar 5, 2026 at 06:31 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 5, 2026 at 06:31 ET

Kura Oncology reported Q4 and full-year 2025 financial results, highlighted by $2.1 million in net product revenue from the initial five weeks of KOMZIFTI™ (ziftomenib) commercial sales following its November 13 FDA approval for R/R NPM1-mutated AML. The company emphasized strong early commercial momentum, rapid payer coverage, and a robust cash position of $667.2 million, which, combined with $180 million in anticipated collaboration payments, is expected to fund operations into Q4 2027 and advance ziftomenib to Phase 3 topline data in frontline AML by 2028.

  • Generated $2.1 million in net product revenue from KOMZIFTI in first five weeks post-FDA approval (Nov 13–Dec 31, 2025)
  • Received $135 million milestone payment from Kyowa Kirin upon product delivery within five days of approval
  • Cash, cash equivalents, and short-term investments totaled $667.2 million as of December 31, 2025
  • Anticipated $180 million in future collaboration payments from Kyowa Kirin to support development through Phase 3 AML data

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access